At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Aug 20, 2026 at 17:25 ET
Two directors at Arrowhead Pharmaceuticals sold a combined $1.19M in open-market sales on August 18, 2026. This is a small cluster relative to the $12.6B market cap (0.009%), and both sellers are directors, not C-suite executives, which per academic literature makes cluster sales a weak signal. The sales are likely liquidity-driven and do not indicate a material bearish view on the company's prospects.
- Two directors sold shares on the same day: Michael S. Perry sold 11,600 shares at $87.30 ($1.01M), and Adeoye Y. Olukotun sold 2,000 shares at $86.96 ($174K).
- Total open-market sales of $1.19M represent only 0.009% of ARWR's $12.6B market cap, well below the 0.1% threshold for materiality.
- Both sellers are directors, not C-suite executives; insider sales by directors are less informative than sales by the CEO or CFO.
- No 10b5-1 plan or pattern information is available, but the small size and director status suggest routine portfolio diversification.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access